In order to understand the SAR around HTT versus beta amyloid/tau aggregate-directed binding and to improve specificity for mHTT, we continued our adaptation of known beta-sheet binders from the Alzheimer’s field and identified a new chemotype with potent binding affinity for recombinant mHTT-derived aggregates, good specific binding in the R6/2 mouse model of HD and brain free fractions predictive of low non-specific binding38. Here, MAPT is linked to Huntington disease.